Opioid Presynaptic Disinhibition of the Midbrain Periaqueductal Grey Descending Analgesic Pathway

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2020 Jan 24

PMID 31971607

Citations 20

Authors

Benjamin K Lau

Bryony L Winters

Christopher W Vaughan

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: The midbrain periaqueductal grey (PAG) plays a central role in modulating pain through a descending pathway that projects indirectly to the spinal cord via the rostroventral medial medulla (RVM). While opioids are potent analgesics that target the PAG, their cellular actions on descending projection neurons are unclear.

Experimental Approach: Patch clamp recordings in voltage- and current-clamp mode were made from acutely prepared PAG slices from animals that received retrograde tracer injections into the RVM.

Key Results: The μ-agonist DAMGO reduced GABAergic evoked inhibitory postsynaptic currents (IPSCs) in retro-labelled, RVM-projecting neurons to a greater extent than in unlabelled neurons. The κ-opioid agonist U69593 reduced evoked IPSCs to a similar extent in both neuronal groups, while the δ-opioid agonist deltorphin-II was without effect. DAMGO and U69593 both produced a reduction in the rate, but not amplitude of spontaneous miniature IPSCs and asynchronous evoked IPSCs in retro-labelled neurons. DAMGO and U69593 also suppressed glutamatergic EPSCs in retro-labelled and unlabelled neurons. The DAMGO inhibition of evoked EPSCs, however, was less than that for evoked IPSCs in retro-labelled, but not unlabelled neurons. In current clamp, DAMGO produced a depolarizing increase in evoked postsynaptic potentials in retro-labelled neurons, but directly inhibited unlabelled neurons.

Conclusion And Implications: These findings suggest that μ-opioids activate the descending analgesic pathway from the midbrain PAG by a combination of presynaptic disinhibition of RVM-projecting neurons and postsynaptic inhibition of presumptive interneurons.

Citing Articles

YTHDF1 in periaqueductal gray inhibitory neurons contributes to morphine withdrawal responses in mice.

Ou C, Zhang K, Mu Y, Huang Z, Li X, Huang W BMC Med. 2024; 22(1):406.

PMID: 39304892 PMC: 11416010. DOI: 10.1186/s12916-024-03634-2.

Single-neuron projectome-guided analysis reveals the neural circuit mechanism underlying endogenous opioid antinociception.

Dou Y, Liu Y, Ding W, Li Q, Zhou H, Li L Natl Sci Rev. 2024; 11(7):nwae195.

PMID: 39045468 PMC: 11264302. DOI: 10.1093/nsr/nwae195.

The Underlying Mechanisms of Sleep Deprivation Exacerbating Neuropathic Pain.

Zhu M, Huang H Nat Sci Sleep. 2023; 15:579-591.

PMID: 37533626 PMC: 10392808. DOI: 10.2147/NSS.S414174.

Cell-type specific molecular architecture for mu opioid receptor function in pain and addiction circuits.

Ochandarena N, Niehaus J, Tassou A, Scherrer G Neuropharmacology. 2023; 238:109597.

PMID: 37271281 PMC: 10494323. DOI: 10.1016/j.neuropharm.2023.109597.

Bulbospinal nociceptive ON and OFF cells related neural circuits and transmitters.

Peng B, Jiao Y, Zhang Y, Li S, Chen S, Xu S Front Pharmacol. 2023; 14:1159753.

PMID: 37153792 PMC: 10157642. DOI: 10.3389/fphar.2023.1159753.

References

Reichling D, Basbaum A . Contribution of brainstem GABAergic circuitry to descending antinociceptive controls: I. GABA-immunoreactive projection neurons in the periaqueductal gray and nucleus raphe magnus. J Comp Neurol. 1990; 302(2):370-7. DOI: 10.1002/cne.903020213. View

Pennock R, Dicken M, Hentges S . Multiple inhibitory G-protein-coupled receptors resist acute desensitization in the presynaptic but not postsynaptic compartments of neurons. J Neurosci. 2012; 32(30):10192-200. PMC: 3418873. DOI: 10.1523/JNEUROSCI.1227-12.2012. View

Gu M, Wessendorf M . Endomorphin-2-immunoreactive fibers selectively appose serotonergic neuronal somata in the rostral ventral medial medulla. J Comp Neurol. 2007; 502(5):701-13. DOI: 10.1002/cne.21343. View

Harding S, Sharman J, Faccenda E, Southan C, Pawson A, Ireland S . The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2017; 46(D1):D1091-D1106. PMC: 5753190. DOI: 10.1093/nar/gkx1121. View

Rossi G, Pasternak G, Bodnar R . Mu and delta opioid synergy between the periaqueductal gray and the rostro-ventral medulla. Brain Res. 1994; 665(1):85-93. DOI: 10.1016/0006-8993(94)91155-x. View

Knudsen L, Petersen G, Norskov K, Vase L, Finnerup N, Jensen T . Review of neuroimaging studies related to pain modulation. Scand J Pain. 2018; 2(3):108-120. DOI: 10.1016/j.sjpain.2011.05.005. View

Williams J, Christie M, Manzoni O . Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev. 2001; 81(1):299-343. DOI: 10.1152/physrev.2001.81.1.299. View

Chieng B, Christie M . Hyperpolarization by opioids acting on mu-receptors of a sub-population of rat periaqueductal gray neurones in vitro. Br J Pharmacol. 1994; 113(1):121-8. PMC: 1510059. DOI: 10.1111/j.1476-5381.1994.tb16183.x. View

Vaughan C, Christie M . Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol. 1997; 498 ( Pt 2):463-72. PMC: 1159215. DOI: 10.1113/jphysiol.1997.sp021872. View

10.

Commons K, Aicher S, Kow L, Pfaff D . Presynaptic and postsynaptic relations of mu-opioid receptors to gamma-aminobutyric acid-immunoreactive and medullary-projecting periaqueductal gray neurons. J Comp Neurol. 2000; 419(4):532-42. DOI: 10.1002/(sici)1096-9861(20000417)419:4<532::aid-cne8>3.0.co;2-6. View

11.

Gutstein H, Mansour A, Watson S, Akil H, Fields H . Mu and kappa opioid receptors in periaqueductal gray and rostral ventromedial medulla. Neuroreport. 1998; 9(8):1777-81. DOI: 10.1097/00001756-199806010-00019. View

12.

Alexander S, Roberts R, Broughton B, Sobey C, George C, Stanford S . Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. Br J Pharmacol. 2018; 175(3):407-411. PMC: 5773976. DOI: 10.1111/bph.14112. View

13.

Vaughan C, Bagley E, Drew G, Schuller A, Pintar J, Hack S . Cellular actions of opioids on periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR-1. Br J Pharmacol. 2003; 139(2):362-7. PMC: 1573857. DOI: 10.1038/sj.bjp.0705261. View

14.

Alexander S, Christopoulos A, Davenport A, Kelly E, Mathie A, Peters J . THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. Br J Pharmacol. 2019; 176 Suppl 1:S21-S141. PMC: 6844580. DOI: 10.1111/bph.14748. View

15.

Drew G, Lau B, Vaughan C . Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J Neurosci. 2009; 29(22):7220-9. PMC: 6666465. DOI: 10.1523/JNEUROSCI.4362-08.2009. View

16.

Depaulis A, Morgan M, LIEBESKIND J . GABAergic modulation of the analgesic effects of morphine microinjected in the ventral periaqueductal gray matter of the rat. Brain Res. 1987; 436(2):223-8. DOI: 10.1016/0006-8993(87)91665-9. View

17.

Lau B, Winters B, Vaughan C . Opioid presynaptic disinhibition of the midbrain periaqueductal grey descending analgesic pathway. Br J Pharmacol. 2020; 177(10):2320-2332. PMC: 7174888. DOI: 10.1111/bph.14982. View

18.

Pennock R, Hentges S . Desensitization-resistant and -sensitive GPCR-mediated inhibition of GABA release occurs by Ca2+-dependent and -independent mechanisms at a hypothalamic synapse. J Neurophysiol. 2016; 115(5):2376-88. PMC: 4922459. DOI: 10.1152/jn.00535.2015. View

19.

Osborne P, Vaughan C, Wilson H, Christie M . Opioid inhibition of rat periaqueductal grey neurones with identified projections to rostral ventromedial medulla in vitro. J Physiol. 1996; 490 ( Pt 2):383-9. PMC: 1158677. DOI: 10.1113/jphysiol.1996.sp021152. View

20.

Gray T, Magnuson D . Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides. 1992; 13(3):451-60. DOI: 10.1016/0196-9781(92)90074-d. View